Nevada Population Health Study to Offer Free 23andMe

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nevada Population Health Study to Offer Free 23andMe Genetic Tests to Community

RENO, Nev., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Nevada-based Renown Health and the Desert Research Institute (DRI) are collaborating with 23andMe , a leading personal genetics company, to launch one of the first community-based population health studies in the U.S. that will combine health, population and genetic information with environmental data and return 23andMe genetic results to study participants.

Funded by the Renown Health Foundation and Nevada's Knowledge Fund, this pilot study will offer community members the opportunity to volunteer for research and gain access to their individual genetic information at no cost.

23andMe's Genotyping Services for Research platform will enable researchers to review genetic data and health-related survey responses from study participants. Combining genetic data with health and population data from Renown, as well as information from environmental databases, DRI scientists will analyze and model public health risks ranging from disease and illness, to the effects of air quality on the health of Nevadans.

"This collaboration addresses one of the fundamental tensions in medicine - which is more important nature or nurture?" explained Anthony Slonim, M.D., DrPH, Renown Health president and CEO. "Clearly, both are important and by combining Renown's de-identified health data, such as 300,000 health histories that are five years or longer and patient population demographics, with other determinants, like social and environment, we can begin to better understand the health and healthcare needs of the people and communities we serve."

The study is open to the first 5,000 northern Nevada residents that qualify.

"This is the ultimate example of population health in action in a community based setting," Dr. Slonim added.

Each participant will receive 23andMe's Personal Genome Service, including more than 65 personalized genetic reports on their health, traits and ancestry. 23andMe is the first and only direct-to-consumer genetics company to provide reports that meet FDA standards.

"We see this as an innovative approach to population health that will benefit Nevadans, and could serve as a model for other states," said Andy Page, president of 23andMe. "It's exciting to have Renown and DRI, leaders in healthcare and research, come together for a comprehensive study of this scale, and to see such a great application of our Genotyping Services for Research platform."

Nevada Governor Brian Sandoval, who announced his participation as one of the first Nevada residents to complete 23andMe's simple DNA test as part of this study, said this offers an unprecedented opportunity for residents of the Silver State.

"Nevada's greatest resource is, and always has been, our people," said Governor Sandoval. "Renown's forward-thinking approach to community healthcare, combined with DRI's data and environmental expertise, will create incredible potential for new scientific discoveries and encourage citizens just like myself to take a proactive role in self-care and ultimately change the way we think about our health moving forward."

"This is a very proud moment for DRI and for Nevada, made possible because of Governor Sandoval's vision for innovation through the Knowledge Fund," added Dr. Robert Gagosian, DRI Acting President.

Researchers hope to build an infrastructure to apply the population health pilot to all approximately 2.8 million Nevada residents – doing so could enable researchers to build predictive models and to look for significant population health factors across demographic variables (gender, age, income, location); and distinct population health strata that consider community health, individual health, and chronic disease variables, as well as their interactions.

"We will begin to understand how environmental factors can help predict who may be at risk, allow for quicker diagnoses, and encourage the development of more precise treatments," said Joseph Grzymski, Ph.D., AIC senior director and principal investigator of the study.

"That understanding, combined with the information we will deliver back to study participants, are the first steps toward a future where access to your personal health data will contribute to a higher overall quality of life for all Nevadans."

For more information and to sign up for the study, visit  https://partners.renown.org/ or call (775) 982-6914. Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is one of the region's largest private employers with a workforce of more than 6,000. It comprises three acute care hospitals, a rehabilitation hospital, skilled nursing, the area's most comprehensive medical group and urgent care network, and the region's largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition of being the first in the region to successfully perform leading-edge medical procedures. For more information, visit www.renown.org .

Desert Research Institute (DRI), the nonprofit research arm of the Nevada System of Higher Education, is a world leader in environmental sciences through the application of knowledge and technologies to improve people's lives throughout Nevada and the world. Supported by Nevada's Knowledge Fund, the DRI Applied Innovation Center (AIC) aims to aid and improve the new, knowledge-based economy in Nevada by integrating DRI's core areas of expertise in hydrologic, atmospheric, earth and ecosystem sciences with data analysis and informatics, visualization, modeling and simulation. More information about DRI's Applied Innovation Center is available at www.dri.edu .

23andMe , Inc. is the leading personal genetics company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. 23andMe has more than one million customers worldwide, with over 80 percent consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at 23andme.com/researchers

Media Contacts: Molly Livingston, Communications  The Abbi Agency on behalf of DRI (510) 898-8220 molly@theabbiagency.com

Andy Kill, Media Relations, 23andMe, Inc. (650) 963-8985 akill@23andMe.com

Stacy Kendall, Director of Communications and New Media, Renown Health (775) 691-7308 news@renown.org

Molly Livingston, Communications The Abbi Agency on behalf of DRI (510) 898-8220

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading